A corresponding subgroup analysis within colon cancer stage III patients showed a trend for improved RFS with high EZH2 index (P=0.097), whereas a similar analysis for CSS was not significant (P=0.14; Figure 3, panels C and D). The gene discussed is EZH2; the disease is malignant colon neoplasm.